Surrozen, Inc. Form 8-K Summary
Business Context and Reporting Period
Surrozen, Inc. (SRZN), a biotechnology company incorporated in Delaware, filed this Current Report on Form 8-K on November 7, 2025. The filing primarily addresses the announcement of financial results for the quarter ended September 30, 2025, and significant changes to executive leadership.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the financial results for the quarter ended September 30, 2025. However, the text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these details.
Material Changes and Executive Appointments
The most significant material change disclosed is the appointment of a new Chief Financial Officer (CFO):
- New CFO: Andrew Maleki was appointed by the Board of Directors on November 6, 2025, effective November 12, 2025.
- Compensation Package:
- Base Salary: $385,000 annually.
- Bonus: Eligible for an annual bonus plan starting in 2026 with a target of 40% of base salary.
- Equity: Granted a non-statutory stock option for 50,000 shares. Vesting schedule includes 25% on the one-year anniversary and 1/48th monthly thereafter.
- Severance: Nine months of base salary and benefits if terminated without cause. In a change-in-control scenario, he receives 12 months of salary, 100% of target bonus, 12 months of benefits, and full acceleration of equity awards.
- Departure: Charles Williams ceased serving as CFO but will continue as Chief Operating Officer and Secretary.
Outlook, Risks, and Management Commentary
The filing does not contain specific management commentary, forward-looking guidance, or a discussion of risks and contingencies beyond the standard legal disclaimers. The financial outlook is contained within the referenced press release (Exhibit 99.1), which is not included in the text of this summary.
Key Facts for Investor Verification
- Verify the specific financial results (revenue, net loss, cash position) for the quarter ended September 30, 2025, by reviewing the attached Press Release (Exhibit 99.1).
- Confirm the effective date of Andrew Maleki's tenure as CFO (November 12, 2025) and the transition of duties from Charles Williams.
- Review the terms of the stock option grant (50,000 shares) and the specific vesting schedule for the new CFO.
- Assess the impact of the leadership change on the company's financial reporting and strategic direction.